Manulife (Manufacturers Life Insurance)’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-11,466
| Closed | -$114K | – | 2952 |
|
|
2025
Q2 | $114K | Buy |
11,466
+584
| +5% | +$4.7K | ﹤0.01% | 2732 |
|
|
2025
Q1 | $65K | Buy |
10,882
+96
| +0.9% | +$705 | ﹤0.01% | 2791 |
|
|
2024
Q4 | $82.8K | Sell |
10,786
-31
| -0.3% | -$266 | ﹤0.01% | 2861 |
|
|
2024
Q3 | $110K | Sell |
10,817
-254
| -2% | -$3.88K | ﹤0.01% | 2844 |
|
|
2024
Q2 | $164K | Buy |
11,071
+690
| +7% | +$9.89K | ﹤0.01% | 2678 |
|
|
2024
Q1 | $142K | Buy |
10,381
+85
| +0.8% | +$926 | ﹤0.01% | 2700 |
|
|
2023
Q4 | $113K | Hold |
10,296
| – | – | ﹤0.01% | 2781 |
|
|
2023
Q3 | $113K | Hold |
10,296
| – | – | ﹤0.01% | 2765 |
|
|
2023
Q2 | $136K | Buy |
+10,296
| New | +$147K | ﹤0.01% | 2742 |
|
|
2022
Q2 | – | Sell |
-8,555
| Closed | -$275K | – | 3070 |
|
|
2022
Q1 | $275K | Sell |
8,555
-2,170
| -20% | -$78.8K | ﹤0.01% | 2565 |
|
|
2021
Q4 | $499 | Sell |
10,725
-136
| -1% | -$4.53K | ﹤0.01% | 2260 |
|
|
2021
Q3 | $293K | Sell |
10,861
-900
| -8% | -$23.5K | ﹤0.01% | 2687 |
|
|
2021
Q2 | $302K | Buy |
11,761
+851
| +8% | +$20.3K | ﹤0.01% | 2807 |
|
|
2021
Q1 | $373K | Buy |
10,910
+4,202
| +63% | +$152K | ﹤0.01% | 2470 |
|
|
2020
Q4 | $227K | Buy |
+6,708
| New | +$178K | ﹤0.01% | 2702 |
|
Other funds holding ITOS
Manulife (Manufacturers Life Insurance)'s ITOS Position: Q3 2025 in Review
Manulife (Manufacturers Life Insurance) sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 11,466 shares — an estimated $114K sold.
Manulife (Manufacturers Life Insurance) first reported a position in ITOS in Q4 2020 and held it in 15 quarters. The position peaked at $373K in Q1 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Manulife (Manufacturers Life Insurance) reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Manulife (Manufacturers Life Insurance) sold 11,466 iTeos Therapeutics shares in Q3 2025, an estimated $114K.
- Manulife (Manufacturers Life Insurance) first reported a position in iTeos Therapeutics in Q4 2020 and held it in 15 quarters.
- Manulife (Manufacturers Life Insurance)'s iTeos Therapeutics position peaked at $373K in Q1 2021.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q3 2025, filed 14 Nov 2025.